CJC-1295 (no dac) 10mg + Ipamorelin 10mg

Within Europe this product is supplied including bacteriostatic water; outside Europe only the peptide vial is provided.

For research use only — not for human or veterinary use.

Product Overview

CJC-1295 (no DAC) + Ipamorelin is a dual-component research peptide blend studied in controlled laboratory environments for its involvement in growth hormone–related signalling pathways, receptor activation dynamics and endocrine feedback modelling. This formulation combines two analytically verified peptides in equal nominal concentrations and is supplied as a lyophilized powder in a sealed 3 ml vial for reproducible in vitro research applications.

Peptide Overview

CJC-1295 (no DAC), also known as MOD GRF 1-29, is a synthetic analogue of growth hormone–releasing hormone that has been widely studied since the early 2000s for its interaction with GHRH receptor pathways and pulsatile endocrine signalling behaviour. Ipamorelin is a selective ghrelin-receptor agonist analogue researched for its receptor specificity and signalling selectivity within endocrine-regulated biochemical systems.

When evaluated together, this peptide combination allows researchers to explore coordinated signalling behaviour, receptor synergy and temporal response patterns within growth hormone–regulated pathways.

Historical Background and Scientific Context

Research into growth hormone–associated peptides expanded significantly during the late twentieth and early twenty-first centuries as laboratories sought to better understand endocrine regulation, pulsatile hormone signalling and receptor-specific activation mechanisms. Dual-peptide models combining GHRH analogues and ghrelin-pathway peptides have since been used as reference tools in preclinical research focused on combined receptor-pathway analysis under controlled experimental conditions.

Mechanistic Focus in Research

• Growth hormone–related receptor signalling analysis
• Endocrine feedback and pulse-modulation modelling
• Receptor selectivity and pathway-interaction research
• Comparative dual-peptide structure–function evaluation
• Controlled in vitro endocrine signalling studies

Analytical Verification (COA)

Independent Liquilabs analysis confirms full validation for Batch GF-CJCIPA10/10-B241. Key analytical results include:

• CJC-1295 (MOD GRF 1-29) Assay Content: 10.67 mg
• CJC-1295 Identification – Retention Time: 0.989
• Ipamorelin Assay Content: 10.06 mg
• Ipamorelin Identification – Retention Time: 1.000
• Endotoxins: below 0.001 EU per mg
• Total Aerobic Microbial Count: not detected
• Total Yeast and Mold Count: not detected
• Heavy Metals: not detected including arsenic, cadmium, cobalt, lead, nickel, mercury and vanadium

All analytical values were obtained using validated chromatographic, spectroscopic and microbiological procedures, ensuring transparent documentation and complete batch traceability.

Research Applications

• Endocrine and growth hormone signalling research
• Receptor interaction and pulse-response studies
• Biochemical feedback-loop modelling
• Comparative dual-peptide pathway evaluation
• Controlled in vitro signalling investigations

Grail Formula Quality

Every Grail Formula research peptide blend undergoes independent third-party laboratory testing for identity, assay accuracy, purity and microbial safety. Each batch is verified for low endotoxin levels, analytical consistency and reproducibility to support reliable scientific research outcomes.

When You Choose Grail Formula…

Researchers receive fully documented peptide materials with batch-number traceability, sealed-vial integrity and transparent laboratory verification. EU shipments include sterile bacteriostatic water; outside the EU only the peptide vial is supplied.

Used solely for in vitro experiments and cannot be:

• Used in clinical trials involving humans
• Administered to humans as part of an experiment or investigation
• Supplied to another party for human investigational use

Verified and analysed with Liquilabs s.r.o. (Czechia)
Dual-peptide blend of CJC-1295 (no DAC) and Ipamorelin
Validated assay content: 10.67 mg and 10.06 mg respectively
Retention time identification and full COA traceability
Endotoxin levels below 0.001 EU per mg
No detectable microbial growth or heavy metals
EU shipments include bacteriostatic water
For research use only — not for human or veterinary use

For laboratory research only. Not intended for human consumption, injection, or cosmetic use.

This product is for research purposes only. Not for human use or diagnostic/therapeutic applications. Keep out of reach of children.